Namrata Kulkarni

Dr. Namrata Kulkarni


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in Cureus
Verified
Journal Article
Open access
PDF file
NKNamrata Kulkarni
Namrata Kulkarni
ARAbhisek Routray
Abhisek Routray
STSantosh Taur
Santosh Taur
Purpose: S. pneumoniae ranks as the fourth-most lethal pathogen globally in terms of fatalities associated with or attributable to resistance. In this study, the Antimicrobial Testing Leadership and Surveillance (ATLAS) analysis from India aims to study the overall antimicrobial susceptibility (AMS) among pneumococcal isolates collected between 2018 and 2021. Methods: Non-duplicate clinically significant S. pneumoniae isolates were collected between 2018 and 2021. In vitro activity of antibiotics was assessed against S. pneumoniae. Susceptibility was confirmed at an International Health Management Associates (IHMA) laboratory using supplied broth microdilution panels (Omron Microscan Systems, Inc., Omron Corp., Kyoto, Japan), according to the Clinical and Laboratory Standards Institute (CLSI) guidelines for all antibiotics. Results: Of the total 86 non−duplicate isolates of Streptococcus pneumoniae collected from the tertiary care centers, the proportion of isolates increased from 8.14% (n=7) in 2018 to 43.02% (n=37) in 2020. Most isolates (n = 18; 48.65%) were collected from the age group of 31-60 years in the year 2020. Erythromycin revealed a decrease in susceptibility from the year 2018 (71.43%) to 2020 (16.22%). A decreased susceptibility of 90% was recorded for levofloxacin in the year 2021. Meropenem revealed a decrease in susceptibility from the year 2018 (85.71%) to 2020 (35.14%). Penicillin susceptibility decreased from 37.5% in 2019 to 27.03% in the year 2020. Clindamycin indicated a 100% susceptibility in the year 2018 which then decreased to 71.88% in 2019 and 56.76% in 2020. Linezolid and vancomycin were found to have uniform susceptibility of 100% throughout the years from 2018 to 2021. Conclusion: An increase in resistance to penicillin and macrolides among S. pneumoniae isolates was observed in the Indian population. Addressing the elevating rates of S. pneumoniae resistance may require pneumococcal conjugate vaccines (PCVs) with expanded serotype coverage and targeted antimicrobial stewardship efforts.

19 October 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
LHLiping Huang
Liping Huang
XLXiuyan Li
Xiuyan Li
ENEugenia Ng
Eugenia Ng
JLJohnnie Leung
Johnnie Leung
SHSheng-Tzu (Alice) Hung
Sheng-Tzu (Alice) Hung
BTBulent Nuri Taysi
Bulent Nuri Taysi
Background: Pneumococcal disease (PD) is a major cause of morbidity and mortality in young children in Asia and globally. Pneumococcal conjugate vaccines (PCVs) have significantly reduced the burden of PD when included in pediatric national immunization programs (NIPs). This study estimates the clinical and economic burden of PD due to serotypes contained in different PCVs in children aged < 5 years in eight Asian countries/territories. Methods: Based on published data, a cohort-based decision analytic model was used to estimate annual PD cases, deaths, and direct medical costs associated with serotypes contained in PCV10, PCV13, PCV15, and PCV20. Results: PD incidence rates were lower in regions with PCV13 in their NIP than those without. Serotypes contained in higher but not lower valency PCVs resulted in a significant incremental clinical and economic burden, although the difference between PCV13 and PCV15 serotypes was generally small. Moving from PCV13 to PCV20 was estimated to result in greater clinical and economic burden reductions. Conclusions: This study demonstrates the remaining and incremental burden of PD from PCV10 to PCV20 serotypes in young children in selected Asian regions. Extending NIP access to higher-valency PCVs with broader serotype coverage and improving vaccine uptake will help prevent morbidity and deaths and save healthcare costs.

20 December 2022 in Cureus
Verified
Journal Article
Open access
SESwetha Es
Swetha Es
STSantosh Taur
Santosh Taur
NKNamrata Kulkarni
Namrata Kulkarni
Patients with concomitant atrial fibrillation (AF) and end-stage renal disease (ESRD) are at increased risk of thrombosis and bleeding. Diligent anticoagulant therapy that prevents major bleeding is essential for stroke prevention. There is a dearth of evidence and guidance on anticoagulation in this patient subset. A validated questionnaire was sent to 500 physicians across India. Anonymized responses from 353 consenting physicians (275 cardiologists and 78 nephrologists) were analyzed. Most physicians opined that the risk of progression of chronic kidney disease (CKD) stages 2-4 to ESRD was 1-5%, and that >10% of patients with ESRD had concomitant AF. Most physicians perceived that the risk of ischemic stroke, major bleeding, and mortality was 30-40%, 40% respectively in patients with concomitant AF and ESRD. The first critical goal for the management of these patients was ‘reduction of thrombotic risk’, followed by ‘prevention of bleeding’ and finally ‘prevention of ESRD progression’ (72.0%, 68.0%, and 67.1% participants, respectively). Most participating physicians (93.8%) preferred non-vitamin K antagonist oral anticoagulants (NOACs) over warfarin for stroke prevention, and most of the participating physicians (94.9%) preferred an adjusted dose rather than the standard dose of the NOAC. Most of the responses were similar between cardiologists and nephrologists. According to the survey response, patients with concomitant AF and ESRD have an increased risk of thrombosis, bleeding, and mortality. NOACs with dose adjustment are the preferred modality for stroke prevention among cardiologists and nephrologists in India, with the primary goal of preventing thrombotic events.

20 February 2023 in Cureus
Verified
Journal Article
Open access
PDF file
NKNamrata Kulkarni
Namrata Kulkarni
STSantosh Taur
Santosh Taur
JKJaspreet Kaur
Jaspreet Kaur
RARavishankar Akolekar
Ravishankar Akolekar
SESwetha Es
Swetha Es
Purpose: The management of patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) requires appropriate antithrombotic regimens for stroke prevention and in-stent thrombosis. Current practice recommendations are largely based on consensus options as there is limited evidence from randomized clinical trials. Hence, by surveying a group of cardiologists across India, we sought to better understand the current practice patterns of using oral anticoagulants (vitamin K antagonist, VKA or non-vitamin K antagonist oral anticoagulant, NOAC) and antiplatelet therapy in those patients in India. Methods: A cross-sectional questionnaire-based survey was conducted across India to better understand the clinical practices in AF management. Results: A total of 151 cardiologists participated in this survey. The most commonly prescribed combination therapy in patients with AF and ACS/undergoing PCI was triple therapy (NOAC + dual antiplatelet [aspirin and P2Y12 inhibitor]) (54.30%) followed by NOAC + single antiplatelet (33.11%). Only 11.26% of cardiologists prescribed VKA + dual antiplatelet therapy. Among anticoagulants, cardiologists prescribed NOACs to 66.11% of patients and VKAs to 25.54% of patients. Among P2Y12 inhibitors, ticagrelor (50.99%) and clopidogrel (47.02%) were the most preferred medication. The physician reported patient adherence rates to NOACs were higher compared to VKAs. Around 41.06% of cardiologists reportedly changed antiplatelet therapy for patients from dual antiplatelet to single antiplatelet therapy in three months; 36.42%, in one month; and 19.21% in six months after PCI. Around 61.59% of cardiologists stopped prescribing antiplatelet therapy for patients by one year. Conclusion: Our survey demonstrated that the majority of cardiologists used triple therapy (NOAC + dual antiplatelet), followed by NOAC + single antiplatelet for managing patients with AF and ACS or undergoing PCI in line with the available guidelines.

9 September 2026 in Acta Microbiologica Hellenica
Verified
Journal Article
Open access
PDF file
BVBalaji Veeraraghavan
Balaji Veeraraghavan
AVAmi Varaiya
Ami Varaiya
ASAnand Shah
Anand Shah
BRBibhudutta Rautaraya
Bibhudutta Rautaraya
AKAnusha Karunasagar
Anusha Karunasagar
NKNamrata Kulkarni
Namrata Kulkarni
Background: Invasive pneumococcal disease (IPD) is predominantly caused by Streptococcus pneumoniae and is associated with high mortality. This vaccine-preventable disease has been a significant public health concern, particularly among children < 5 years and adults > 50 years in India. Pneumococcal vaccines help prevent pneumococcal infections caused by certain strains of S. pneumoniae, but diagnostic challenges in India hinder disease management. Methods: The objective of this expert panel discussion is to deliberate upon the pathogenesis and epidemiology of S. pneumoniae in India, techniques for overcoming the diagnostic challenges in the isolation and detection of S. pneumoniae, and to explore opportunities for partnerships between clinicians and microbiologists to bridge gaps. A non-systematic, targeted literature search was conducted to identify studies supporting key themes of expert panel discussion. Eight microbiologists, one infectious disease, one pediatrics and neonatology, and one respiratory medicine specialist from different parts of India participated in the discussion. Results: The panelists reiterated that while culture is the gold standard, multiplex real-time polymerase chain reaction and BioFire® FilmArray® technology have been the most common diagnostic methods for the detection of S. pneumoniae in India, especially in tier 1 cities. Conclusions: This article elucidates the challenges faced by microbiologists and clinicians in isolating and detecting the pathogen, and proposes solutions to determine the true burden of pneumococcal disease in India. This information could further inform public health policy and vaccination strategies.

3 November 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
STSantosh Taur
Santosh Taur
MKMukundraj Satyaranjan Keny
Mukundraj Satyaranjan Keny
NKNamrata Kulkarni
Namrata Kulkarni
Background: Pneumococcal disease remains a major public health concern in India, with significant prevalence in both children and adults. Pneumococcal conjugate vaccine (PCV) 13 provides high serotype coverage in children and in adults; however, non-vaccine serotypes are emerging. Rising antimicrobial resistance and limited local serotype data hinder effective disease control and vaccine policy. This meta-analysis consolidates evidence on pneumococcal serotype distribution, antimicrobial resistance (AMR)/non-susceptibility trends, and PCV coverage in the Indian population across pediatric and adult age groups. Methods: A systematic review and meta-analysis were conducted on pneumococcal serotype distribution and AMR/non-susceptibility patterns using Indian publications from 2007 to 2024. Comprehensive searches were performed in PubMed, Google Scholar, and EMBASE. Data were analyzed using a random-effects model in R (version 4.4.1), with heterogeneity assessed via the I² test. Serotype distribution was further stratified into invasive pneumococcal disease (IPD), carriage, and community-acquired pneumonia (CAP) subgroups. Results: Twenty-six studies, comprising 4,253 Streptococcus pneumoniae (S. pneumoniae) isolates, were included with 24 studies from the pre-Universal Immunization program (UIP) period. Among pediatric IPD estimates supported by multiple studies, serotype 14 (14.15%), serotype 19F (11.39%), and serotype 6B (10.17%) were most frequent. Higher estimates for pediatric IPD serogroups 6 (25%), 18 (12.5%), and 19 (10%) were each derived from one 40-isolate study and were considered exploratory. In the adult IPD population, serotype 1 (11.69%), and serotypes 23F (6.84%), and 19F (6.71%) were the most common. Adult CAP estimates came from one 50-isolate study, in which serotype 19A (14%) and serotype 8 (10%) were most frequent. AMR/non-susceptibility was consistently highest for cotrimoxazole/trimethoprim-sulfamethoxazole across pediatric IPD (86.16%) and adult IPD (85.24%) populations as well as in adult CAP (74%). Penicillin non-susceptibility was estimated at 14.33% (95% CI: 5.22–33.72) in pediatric IPD, although considerable between-study heterogeneity was observed (I² = 97.15). Accordingly, this pooled estimate should be interpreted in the context of the substantial variability across the included studies. Conclusion: Among pediatric IPD estimates supported by multiple studies, serotype 14, serotype 19F, and serotype 6B were most frequent. In the adult IPD population, serotype 1, and serotypes 23F, and 19F were the most common. Cotrimoxazole/trimethoprim-sulfamethoxazole showed the highest resistance. Among PCV formulations assessed, PCV20 showed the highest serotype coverage. There is a need for continuous, geographically broader surveillance of serotypes and AMR patterns in pneumococcal disease to guide the national vaccination policies and choice of PCVs.